Access to innovation through the French Expanded-Access Program and clinical trials in patients with malignant melanoma.

被引：0
|
作者：
Christen, Claire
Belgodere, Laetitia
Guillot, Bernard
Kerouani-Lafaye, Ghania
Brunel, Liora
Turcry, Florence
Monard, Adrien
Grude, Francoise
Guyader, Gaelle
Boudali, Lotfi
Albin, Nicolas
机构：
[1] French Natl Agcy Med & Hlth Prod Safety ANSM, St Denis, France
[2] CHU Montpellier, Univ Hosp Montpellier, Dermatol Dept, Montpellier, France
[3] Grp Hosp Mutualiste Grenoble, Grenoble, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e22030
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program
    Gonzalez-Cao, M.
    Arance, A.
    Piulats, J. M.
    Marquez-Rodas, I.
    Manzano, J. L.
    Berrocal, A.
    Crespo, G.
    Rodriguez, D.
    Perez-Ruiz, E.
    Berciano, M.
    Soria, A.
    Castano, A. G.
    Espinosa, E.
    Montagut, C.
    Alonso, L.
    Puertolas, T.
    Aguado, C.
    Royo, M. A.
    Blanco, R.
    Rodriguez, J. F.
    Munoz, E.
    Mut, P.
    Barron, F.
    Martin-Algarra, S.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (06): : 761 - 768
  • [22] Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program
    M. González-Cao
    A. Arance
    J. M. Piulats
    I. Marquez-Rodas
    J. L. Manzano
    A. Berrocal
    G. Crespo
    D. Rodriguez
    E. Perez-Ruiz
    M. Berciano
    A. Soria
    A. G. Castano
    E. Espinosa
    C. Montagut
    L. Alonso
    T. Puertolas
    C. Aguado
    M. A. Royo
    R. Blanco
    J. F. Rodríguez
    E. Muñoz
    P. Mut
    F. Barron
    S. Martin-Algarra
    Clinical and Translational Oncology, 2017, 19 : 761 - 768
  • [23] Long-term therapy with itolizumab is safe and effective for patients with moderate to severe psoriasis: Results from an expanded-access program
    Lincheta, Leopoldina Falcon
    Napoles, Yaimarelis Saumell
    Lovio, Olaine R. Gray
    Fuentesfria, Alina M. Viqueira
    Alonso, Teresita Perez
    Romagoza, Maritza Batista
    Rodriguez, Aleida Urquiza
    Fernandez, Beatriz Mantecon
    Jerez, Heber A. Bautista
    Armas, Damarys Fernandez de
    Matute, Eldenida S. Martinez
    Garcia, Yakelin Leon
    Fernandez, Diana K. Oramas
    Chavez, Yaneisy Marrero
    Lorente, Aymara Fernandez
    Hung, Ana R. Valls
    Lorenzo-Luaces, Patricia
    Silva, Carmen Valenzuela
    Moreno, Ernesto
    Hernandez-Casana, Patricia
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 134
  • [24] Single-Center Experience With Ipilimumab in an Expanded Access Program for Patients With Pretreated Advanced Melanoma
    Wilgenhof, Sofie
    Du Four, Stephanie
    Vandenbroucke, Frederik
    Everaert, Hendrik
    Salmon, Isabelle
    Lienard, Danielle
    Del Marmol, Veronique
    Neyns, Bart
    JOURNAL OF IMMUNOTHERAPY, 2013, 36 (03) : 215 - 222
  • [25] Ipilimumab in patients with melanoma brain metastases, a single-center experience in an expanded access program
    Du Four, Stephanie
    Wilgenhof, Sofie
    Seghers, Amelie Clementine
    Duerinck, Johnny
    Neyns, Bart
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [26] IPILIMUMAB IN PATIENTS WITH MELANOMA BRAIN METASTASES, A SINGLE-CENTER EXPERIENCE IN AN EXPANDED ACCESS PROGRAM
    Du Four, S.
    Wilgenhof, S.
    Neyns, B.
    NEURO-ONCOLOGY, 2012, 14 : 79 - 79
  • [27] Correction to: Providing Patients with Critical or Life-Threatening Illnesses Access to Experimental Drug Therapy: A Guide to Clinical Trials and the US FDA Expanded Access Program
    Marjorie A. Speers
    Pharmaceutical Medicine, 2020, 34 : 295 - 295
  • [28] Durable remissions with Ipilimumab in pretreated metastatic malignant melanoma (MMM) patients (pts): Results of a South African Expanded Access Program (EAP).
    Vorobiof, Daniel A.
    Rapoport, Bernardo Leon
    Dreosti, Lydia Mary
    Nosworthy, Adam L.
    McAdam, Georgina Laird
    Jordaan, Johann Petrus
    Donato, Bonnie M. K.
    Qatami, Lara
    Duvenhage, Hennie
    Stander, Tienie
    Bergh, Margreet
    De Beer, Janetta
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] Durable remissions with ipilimumab in pretreated metastatic malignant melanoma (MMM) patients (pts). Results of a South African Expanded Access Program (EAP)
    Rapoport, B.
    Vorobiof, D.
    Dreosti, L.
    Nosworthy, A.
    McAdam, G.
    Jordaan, A. P.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S674 - S674
  • [30] Toxicity associated with ipilimumab and nivolumab (Ipi plus Nivo) combination therapy in melanoma patients (pts) treated at a single-institution under an expanded-access program (EAP).
    Friedman, Claire Frances
    Navid-Azarbaijani, Pedram
    Shoushtari, Alexander Noor
    Campbell, Shonnette C.
    Callahan, Margaret K.
    Momtaz, Parisa
    Prempeh-Keteku, Nana A.
    Postow, Michael Andrew
    Shames, Yelena
    Wolchok, Jedd D.
    Chapman, Paul B.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345